Abstract
Background & aims
Histone deacetylases (HDACs) are important regulators of chromatin involved in silencing tumor suppressor genes. We examined mutation of HDAC2 and examined consequences of HDAC2 loss.Methods
Colon cancer cell lines and primary cancers were examined for mutations in HDAC2 by direct sequencing and capillary electrophoresis. Promoter methylation was determined using methylation-specific polymerase chain reaction in primary tumors. Sensitivity to HDAC inhibitors and resistance in vitro used colon cancer cell lines.Results
HDAC2 mutations in the poly(A) tract in exon 1 result in a frameshift and premature stop codon. These were found in microsatellite instability (MSI) cell lines and 43% of MSI colon cancers, but only 7% of microsatellite stable cancers. Mutation was associated with complete or regional tumor specific loss of HDAC2 protein. Inactivation of HDAC2 was not associated with large-scale changes in promoter region methylation, but rather is a consequence of epigenetic MLH1 inactivation leading to MSI. HDAC2 mutation results in apoptotic resistance to HDAC inhibitors (trichostatin A or suberoylanilide hydroxamic acid), despite induction of global histone acetylation. Differential induction of apoptosis by HDAC inhibitors is mediated by the proapoptotic gene APAF1, as shown by specific APAF1 induction only in cell lines with functional HDAC2, HDAC2 protein localization to the APAF1 promoter by chromatin immunoprecipitation, siRNA knockdown of HDAC2 leading to up-regulation of APAF1, and stable knockdown of APAF1 reducing apoptotic response to HDAC inhibitors.Conclusions
Frequent HDAC2 mutations are found in MSI tumors and HDAC2 plays a major role in mediating apoptotic response to HDAC inhibitors through direct regulation of APAF1.References
Articles referenced by this article (37)
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Cancer Cell, (5):455-463 2004
MED: 15144953
The role of histone acetylation in SMN gene expression.
Hum Mol Genet, (9):1171-1182 2005
MED: 15772088
Negative and positive regulation of gene expression by mouse histone deacetylase 1.
Mol Cell Biol, (21):7913-7928 2006
MED: 16940178
Gene silencing in cancer in association with promoter hypermethylation.
N Engl J Med, (21):2042-2054 2003
MED: 14627790
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.
J Natl Cancer Inst, (15):1210-1216 2000
MED: 10922406
Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis.
Cell Cycle, (10):1240-1242 2004
MED: 15477762
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Nat Genet, (5):566-569 2006
MED: 16642021
Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer.
Cancer Res, (12):3133-3137 2003
MED: 12810640
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Clin Cancer Res, (6):1669-1677 2008
MED: 18347167
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer.
Cancer Res, (24):7213-7218 2002
MED: 12499261
Show 10 more references (10 of 37)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Article citations
Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.
NPJ Syst Biol Appl, 10(1):68, 21 Jun 2024
Cited by: 0 articles | PMID: 38906870 | PMCID: PMC11192759
Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors.
Epigenetics, 19(1):2309824, 18 Feb 2024
Cited by: 0 articles | PMID: 38369747 | PMCID: PMC10878021
Pathogenesis and biomarkers of colorectal cancer by epigenetic alteration.
Intest Res, 22(2):131-151, 01 Feb 2024
Cited by: 0 articles | PMID: 38295766 | PMCID: PMC11079515
Review Free full text in Europe PMC
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine.
Cell Death Discov, 10(1):28, 15 Jan 2024
Cited by: 6 articles | PMID: 38225241 | PMCID: PMC10789753
Review Free full text in Europe PMC
Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification.
Cell Death Differ, 30(5):1305-1319, 02 Mar 2023
Cited by: 7 articles | PMID: 36864125 | PMCID: PMC10154422
Go to all (28) article citations
Data
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Nat Genet, 38(5):566-569, 16 Apr 2006
Cited by: 155 articles | PMID: 16642021
Transforming pathways unleashed by a HDAC2 mutation in human cancer.
Oncogene, 27(28):4008-4012, 11 Feb 2008
Cited by: 20 articles | PMID: 18264134
Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity.
Cancer Res, 67(7):3145-3152, 01 Apr 2007
Cited by: 98 articles | PMID: 17409421
Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
IDrugs, 10(8):557-561, 01 Aug 2007
Cited by: 38 articles | PMID: 17665331
Review